IHMA

What IHMA does

International Health Management Associates (IHMA) is a privately held contract microbiology laboratory services company founded in 1992 that supports antimicrobial drug development for pharmaceutical, biotechnology, and diagnostic companies. The company operates CAP-accredited, CLIA-certified central microbiology laboratories in Schaumburg, Illinois (USA), Monthey (Switzerland), Gurugram (India), and Shanghai (China), delivering services across the full drug development lifecycle from discovery through commercialization. Its customer base spans 1,500+ institutions across more than 80 countries, primarily anti-infective drug developers and surveillance programs.

IHMA's core assets include a Bacterial Repository comprising hundreds of thousands of characterized clinical isolates sourced from 80+ countries, supported by proprietary service programs such as the Manufacturers Interface and Performance Program (MIPP), the Antimicrobial Voluntary Evaluation Program (AVEP), and the Analysis of Resistance to Antifungals (ARIA) program. The company provides central laboratory microbiology services for clinical trials, antimicrobial resistance surveillance studies, and specialized microbiology testing. The repository and surveillance methodology together form the data backbone that differentiates IHMA from generic reference labs, with regulatory credentials (CAP/CLIA) and 30+ years of curated isolate history creating high barriers to reproduction.

The business operates as a B2B professional services provider under customized contract arrangements with pharmaceutical and biotech sponsors. Revenue is not publicly disclosed; revenue generation follows typical CRO mechanics — per-study testing fees, surveillance program subscriptions, and isolate/repository licensing — with the newer ARIA antifungal program and Asia-Pacific laboratories representing recent extensions of the same underlying model into adjacent therapeutic and geographic segments.

Name

IHMA

Legal name

International Health Management Associates, Inc.

Website

https://ihma.com

Company type

Private

Operating status

Operating

Short description

International Health Management Associates (IHMA) is a contract microbiology laboratory services company supporting pharmaceutical, biotechnology, and diagnostic companies with antimicrobial drug development, operating CAP/CLIA-certified labs in the US, Switzerland, India, and China, and maintaining a global Bacterial Repository of characterized isolates.

Ownership category

akta.pro rank

Product category

Microbiology Laboratory Services for Antimicrobial Drug Development

NAICS

Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF)

akta.pro secondary industries

Microbiology LIS/LIMS (HLACAMAD), Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC), Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC), Healthcare-Associated Infection (HAI) & Antimicrobial Resistance (AMR) Surveillance (HLAJABAH), Antimicrobial Stewardship (HLAKAGAG)

Keywords

• Microbiology laboratory services
• Antimicrobial drug development
• Clinical trial central lab
• Antimicrobial resistance surveillance
• Bacterial biorepository services

Headquarters

HQ city

Schaumburg

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Laboratory Services for Antimicrobial Development: IHMA provides central, reference, and clinical research laboratory services supporting all phases of anti-infective therapy development from discovery through commercialization. Services include microbiology testing, surveillance studies, clinical trial support, and regulatory submission preparation.
2. Antimicrobial Resistance Surveillance Services: Ongoing surveillance programs monitoring antimicrobial susceptibility trends for antibacterial and antifungal agents in clinical development and post-approval, typically conducted over multiple years.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

IHMA provides specialized microbiology laboratory services and a global Bacterial Repository to pharmaceutical, biotechnology, and diagnostic companies developing antimicrobial products. Services span drug discovery, clinical development, regulatory submission, and commercialization, including clinical trial central microbiology testing, antimicrobial resistance surveillance, and molecular epidemiology characterization. The company operates CAP- and CLIA-accredited laboratories in the United States, Switzerland, India, and China.

Product overview

IHMA offers a unified suite of microbiology laboratory services supporting all phases of antimicrobial drug development, from discovery through commercialization. The portfolio centers on four integrated service areas: Drug Discovery (Bacterial Repository, Specialized Microbiology Laboratory Services, Clinical Scientific Expertise), Clinical Development (Central Laboratory Microbiology Services, Specialized Microbiology Laboratory Services, Clinical Scientific Expertise), Regulatory Submissions (Antimicrobial Resistance Surveillance, Central Laboratory Microbiology Services, Specialized Microbiology Laboratory Services, Clinical Scientific Expertise), and Commercialization (Antimicrobial Resistance Surveillance, AVEP, MIPP, Specialized Microbiology Laboratory Services, Clinical Scientific Expertise). The recent addition of the Analysis of Resistance to Antifungals (ARIA) program extends their capabilities to antifungal agents. Key differentiators include their global bacterial repository, CAP accreditation, CLIA certification, and experience supporting hundreds of antimicrobial agents.

Differentiator

Problem solved

Functional benefit

Products and services

• Bacterial Repository A global repository of authenticated bacterial isolates available to pharmaceutical, biotechnology, and diagnostic clients for research, development, validation, and surveillance activities. Serves anti-infective drug developers and diagnostic manufacturers needing characterized clinical strains.
• Clinical Scientific Expertise Scientific consulting and expert microbiology services supporting antimicrobial drug development programs for pharmaceutical and biotechnology sponsors across discovery, clinical, regulatory, and commercialization phases.
• Specialized Microbiology Laboratory Services Antimicrobial susceptibility testing, molecular characterization, and resistance profiling performed in CAP/CLIA-accredited laboratories for pharmaceutical and biotech sponsors throughout the drug development lifecycle.
• Central Laboratory Microbiology Services Central microbiology testing for multi-site clinical trials of anti-infective agents, with global sample logistics across laboratories in the United States, Switzerland, India, and China.
• Antimicrobial Resistance Surveillance Post-marketing surveillance programs (AVEP) and molecular epidemiology services (MIPP) that monitor resistance trends and pathogen profiles for sponsors of approved antimicrobial products.
• ARIA Interpretive Intelligence Proprietary interpretive intelligence platform supporting resistance data interpretation and decision support for antimicrobial drug developers, clinicians, and diagnostic manufacturers.
• AVEP (Antimicrobial Surveillance Program) Proprietary antimicrobial resistance surveillance program providing longitudinal resistance data for sponsors of approved anti-infective products and diagnostic manufacturers.
• MIPP (Molecular Investigation of Pathogen Profiles) Molecular epidemiology service characterizing pathogen resistance mechanisms and clonal relationships for pharmaceutical, biotech, and diagnostic clients.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Module InnovationsminorStrategic or Co-development Partner · 21 December 2021Module Innovations co-presented AMR Awareness Talks with IHMA in December 2021, featuring speakers from both organizations discussing antimicrobial resistance topics.
• C-CAMP (Centre for Cellular and Molecular Platforms)coreStrategic or Co-development Partner · 14 December 2020C-CAMP and IHMA partnered to develop innovative solutions for combating antimicrobial resistance (AMR). This collaboration enhanced IHMA's global support of anti-infective drug development capabilities in India, working with Indian biotech companies and research institutions.
• MedpacecoreStrategic or Co-development PartnerIHMA and Medpace offer specialized microbiology expertise in a fully integrated global central laboratory environment. The partnership delivers seamless sample management, tracking, data reporting, and collaborative project services for clinical trials, combining Medpace's central laboratory capabilities with IHMA's microbiology specialization.
• CLSI (Clinical and Laboratory Standards Institute)coreStrategic or Co-development PartnerIHMA is a member of CLSI and actively participates in CLSI meetings and committees, including the Antimicrobial Susceptibility Testing Subcommittee. Multiple IHMA team members hold positions in CLSI working groups including Chair of the Anaerobe Working Group, Liaison for Text and Tables Working Group, and member of the Bacterial Methods Working Group.
• AMR InsightsminorOthersIHMA is listed as a partner of AMR Insights, an organization focused on antimicrobial resistance awareness and education.
• PACEminorOthersIHMA is a member/partner of PACE (organization related to antimicrobial resistance).

Scale indicators6 records

Recent moves9 records

Expansion highlights4 records

Broad incumbents

• Charles River Laboratories: Charles River offers discovery, manufacturing, and safety testing services including microbiology capabilities for anti-infective development. Broader incumbent: comparable B2B model serving pharma/biotech but spanning multiple modalities beyond antimicrobial lab services.
• ICON Central Laboratories: ICON (post-PRA Health) operates global central laboratories supporting clinical trials across therapeutic areas. Broader incumbent: similar central lab offering for pharma/biotech sponsors with broader therapeutic reach than IHMA.
• Q² Solutions (IQVIA Central Labs): Q² Solutions provides global central laboratory services for clinical trials across multiple therapeutic areas, including microbiology. Broader incumbent: operates at greater scale and therapeutic breadth than IHMA but with similar central lab positioning for pharma/biotech sponsors.
• Labcorp Drug Development (Fortrea): Labcorp (and Fortrea for clinical operations) offers large-scale central laboratory and clinical trial services globally, including microbiology offerings. Broader incumbent: serves the same pharmaceutical/biotech customers with a much wider service menu but is less specialized than IHMA in antimicrobial surveillance and discovery microbiology.
• PPD Global Central Labs (Thermo Fisher): PPD (now part of Thermo Fisher Scientific) provides clinical research and central laboratory services including specialty microbiology. Broader incumbent: much larger CRO with central labs serving the same customer base, though antimicrobial microbiology is not a stated focus area.

Regional players

• ARUP Laboratories: ARUP is a non-profit clinical and reference laboratory operated by the University of Utah, performing high-complexity microbiology and serving as a reference lab. Regional player: comparable reference/clinical lab model with deep microbiology expertise but primarily U.S.-focused and not structured around drug development.

Others

• bioMérieux: bioMérieux is a leading in vitro diagnostics company manufacturing microbiology identification and antimicrobial susceptibility testing systems (e.g., VITEK). Adjacent ecosystem participant: not a direct competitor for IHMA's lab services, but rather an IVD manufacturer whose devices IHMA supports through MIPP/AVEP, with IHMA Senior Scientist Mark G. Wise previously employed at bioMérieux.

Direct peers

• ACM Global Central Laboratory: ACM Global is a mid-sized central laboratory providing clinical trial testing including microbiology and specialized assays. Direct peer: comparable scale, similar B2B clinical trial lab model, and competing for global biopharma central lab contracts.
• Frontage Laboratories: Frontage provides laboratory services spanning bioanalytical, CMC, and microbiology for drug development. Direct peer: comparable size and B2B contract lab model supporting pharma/biotech sponsors, though with broader non-microbiology focus.
• Eurofins Central Laboratory: Eurofins Central Laboratory is a global clinical trial central lab network offering microbiology, specialty testing, and biosafety services comparable to IHMA. Direct peer: IHMA's CSO Daniel F. Sahm previously served as CSO at Eurofins Global Central Laboratory, and both companies serve global clinical trials with microbiology specialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IHMA